



CPT® Editorial Summary of Panel Actions June 2022 Electronic Meeting

CPT® Editorial Summary of Panel Actions June 2022

Please be aware that this action is a reflection of the discussion at the most recent telephonic Panel meeting.

The SARS-CoV-2 Vaccine product CPT code and immunization CPT codes can be found on the [AMA Website](#).

Addition of 1 Category 1 code (0083A) accepted by the CPT Editorial Panel.

Code 0083A and all related references will be published in CPT 2023. Guidelines and parenthetical notes are only effective for codes that have received FDA Emergency Use Authorization (EUA) approval.

Updated effective date for code 0074A. Add the term “patient age” to the guidelines in the Medicine Immunization Administration for Vaccines/Toxoids section.

Name	Code #	Description of Editorial Panel Action	Effective Date
Immunization administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines only	#●0083A	Accepted addition of code 0083A for immunization administration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine only. Each administration code is specific to each individual vaccine product (eg, 91308); accepted revision of Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) Vaccines, a quick reference guide to showcase the coding structure for SARS-CoV-2 vaccine CPT reporting, to include code 00083A; and accepted revision of the guidelines in the Medicine Services, Immunization Administration for Vaccines/Toxoids, and the Vaccines, Toxoid subsections.	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration